Antibody-drug conjugates (ADCs) represent an important class of cancer therapies that have revolutionized the treatment paradigm of solid tumors. To date, many ongoing studies of ADC combinations with a variety of anticancer drugs, encompassing chemotherapy, molecularly targeted agents, and immunotherapy, are being rigorously conducted in both preclinical studies and clinical trial settings. Nevertheless, combination therapy does not always guarantee a synergistic or additive effect and may entail overlapping toxicity risks. Therefore, understanding the current status and underlying mechanisms of ADC combination therapy is urgently required. This comprehensive review analyzes existing evidence concerning the additive or synergistic effect of ADCs with other classes of oncology medicines. Here, we discuss the biological mechanisms of different ADC combination therapy strategies, provide prominent examples, and assess their benefits and challenges. Finally, we discuss future opportunities for ADC combination therapy in clinical practice.

中文翻译：

---

实体瘤中抗体药物偶联物联合疗法的前景和挑战


抗体药物偶联物 (ADC) 代表了一类重要的癌症疗法，彻底改变了实体瘤的治疗模式。迄今为止，许多正在进行的 ADC 与多种抗癌药物（包括化疗、分子靶向药物和免疫治疗）组合的研究正在临床前研究和临床试验环境中严格进行。然而，联合治疗并不总能保证协同或相加效应，并且可能带来重叠的毒性风险。因此，迫切需要了解ADC联合治疗的现状和潜在机制。这篇综合综述分析了有关 ADC 与其他类别肿瘤药物的相加或协同效应的现有证据。在这里，我们讨论不同 ADC 联合治疗策略的生物学机制，提供突出的例子，并评估它们的益处和挑战。最后，我们讨论了 ADC 联合治疗在临床实践中的未来机会。